中国实验血液学杂志最新文献

{"title":"[Clinical Features and Prognosis of 23 Cases of Adult T-Cell Leukemia/Lymphoma in Ningde City, Fujian Province and Efficacy of Antiviral Therapy --a Retrospectively Analysis].","authors":"Chang-Gui Wang, Ren-Li Chen, Xiao-Lan Lai","doi":"10.19746/j.cnki.issn.1009-2137.2025.02.008","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.02.008","url":null,"abstract":"<p><strong>Objective: </strong>To analyze the clinical characteristics and prognosis of patients with adult T-cell leukemia/lymphoma (ATLL) in Ningde City, Fujian Province.</p><p><strong>Methods: </strong>We retrospectively collected 23 cases diagnosed with adult T-cell leukemia/lymphoma in the Hematology Department of Ningde Hospital Affiliated to Ningde Normal University from 2014 to 2023, the clinical characteristics of patients were summarized and the prognosis was analyzed. The survival of patients treated with chemotherapy alone and chemotherapy combined with antiviral therapy was compared.</p><p><strong>Results: </strong>All 23 patients were from the coastal endemic area of Fujian (Ningde City), 12 males and 11 females. The median age of onset was 59 (range: 31-84) years old. The clinical types were acute (18 cases) or lymphomatous (5 cases), and no smoldering or chronic type was seen. The most common clinical manifestations were, in order of prevalence, 20 cases of leukocytosis, 19 cases of lymph node enlargement, 13 cases of skin lesions, 13 cases of hypercalcemia. There was an elevation of lactate dehydrogenase (LDH) levels in more than 90% of cases, and β₂-microglobulin levels were elevated in 11 cases. Twelve of the 23 patients were treated with chemotherapy (partly in combination with antiviral therapy), one underwent allogeneic hematopoietic stem cell transplantation. The median overall survival of all patients was 2.3(0.2-13) months. Median survival was 3(2-11) months in the chemotherapy combined with antiviral therapy group, while that of the chemotherapy alone group was 2(0.2-13) months.</p><p><strong>Conclusion: </strong>The clinical manifestations of adult T-cell leukemia/lymphoma in Ningde city, Fujian province are characteristic and the prognosis is unfavorable. Antiviral therapy may contribute to an improvement in the prognosis.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 2","pages":"359-364"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144053030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Metabolic Characteristics of ¹⁸F-FDG in Different Types of Myeloid Leukemia Cells and Tumor-Bearing Nude Mice].","authors":"Xi Chen, Qin Yan, Xiang Qin, Li Zhang, Yue Feng, Qian Chen, Si-Li Long, Wen-Jun Liu","doi":"10.19746/j.cnki.issn.1009-2137.2025.02.003","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.02.003","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the metabolic characteristics of ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG) in myeloid leukemia by in vitro culture of myeloid leukemia cells and construction of tumor-bearing nude mouse model.</p><p><strong>Methods: </strong>U937, THP-1, HL60 and K562 cells were cultured <i>in vitro</i>. The cells in logarithmic growth phase (l×10 ⁵ cells/well) were added with ¹⁸F-FDG, and the uptake rate of ¹⁸F-FDG was measured at 15, 30, 60 and 120 min after addation, respectively. The four kinds of cells were inoculated subcutaneously into the hind limbs of nude mice to establish a tumor-bearing nude mouse model. When the tumor size was about 500 mm³, ¹⁸F-FDG was injected through the tail vein of the mice, and positron emission tomography/computed tomography was performed at 60 min after injection. The morphology of tumor-bearing cells was observed by hematoxylin-eosin (HE) staining in serial pathological sections.</p><p><strong>Results: </strong>After co-incubation with ¹⁸F-FDG, the ¹⁸F-FDG uptake rates of U937 cells were significantly higher than THP-1, HL60 and K562 cells at 4 time points (all <i>P</i> <0.05), and THP-1 cells were higher than K562 cells (all <i>P</i> <0.05). The uptake rate of ¹⁸F-FDG by leukemia cells was rapid in the first 60 min, then tended to be stable. Pathological analysis showed that subcutaneous inoculation of U937, THP-1, HL60 and K562 cells could successfully establish tumor-bearing nude mouse models of myeloid leukemia. The ¹⁸F-FDG uptake value in U937 tumor-bearing nude mice was significantly higher than THP-1, HL60 and K562 tumor-bearing nude mice (all <i>P</i> <0.01). The ¹⁸F-FDG uptake values in THP-1 and HL60 tumor-bearing nude mice were significantly higher than that in K562 tumor-bearing nude mice (both <i>P</i> <0.01).</p><p><strong>Conclusion: </strong>The tumor-bearing nude mouse model of myeloid leukemia can be successfully constructed by subcutaneous inoculation. The ¹⁸F-FDG uptake rate of acute myeloid leukemia (AML) cells is higher in cells cultured in vitro and tumor-bearing nude mouse model. ¹⁸F-FDG may have better clinical application value for AML.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 2","pages":"325-330"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144027481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Efficacy of Pomalidomide in Multiple Myeloma with Extramedullary Disease].","authors":"Ping-Ping Zhang, Meng Wang, Yan-Ping Wu, Jia-Jia Li","doi":"10.19746/j.cnki.issn.1009-2137.2025.02.022","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.02.022","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the efficacy and safety of pomalidomide in the treatment of multiple myeloma (MM) with extramedullary disease (EMD).</p><p><strong>Methods: </strong>The clinical data of 40 pomalidomide-based multiple myeloma patients with extramedullary disease admitted to the Department of Hematology, the First Affiliated Hospital of Bengbu Medical College from February 2019 to August 2023 were retrospectively analyzed.</p><p><strong>Results: </strong>Among the 40 patients, 8 were newly diagnosed with EMD and 32 were refractory/relapsed EMD. There were 21 cases with bone-related extramedullary disease (EM-B) and 19 cases with soft tissue-related extramedullary disease (EM-S). Compared with the EM-B group, the EM-S group exhibited lower LDH levels, an elevation in LDH and a shorter progression-free survival(PFS) (11 months <i>vs</i> 21.5 months, <i>P</i> =0.0363). 32 patients completed 3 courses of treatment, and the short-term efficacy was evaluated. There was no significant difference in the rate of use of 3 or more drugs and ASCT treatment between NDMM group and RRMM group (87.50% <i>vs</i> 93.75%, <i>P</i> >0.05; 25.00% <i>vs</i> 15.63%, <i>P</i> >0.05). Compared with the RRMM group, the overall response rate (ORR) of the NDMM patients was significantly higher (83.33% <i>vs</i> 57.70%, <i>P</i> < 0.05). The deep remission rate (VGPR+CR) of the NDMM group was better than that of the RRMM group (50.00% <i>vs</i> 29.62%, <i>P</i> < 0.05), and the non-response rate (SD+PD) of the NDMM group was significantly lower than that of the R/RMM group (33.33% <i>vs</i> 65.38%, <i>P</i> < 0.05), while the partial remission rate (PR) and mortality rate of the NDMM were not significantly different from those of the RRMM group(<i>P</i> >0.05). With a median follow-up of 26 months, the median PFS was 19 months. Univariate analysis showed that EM-S, high-risk genetic abnormalities, induction therapy did not achieve partial response(PR) or better, and more than 2 lines of treatment failure were associated with shorter PFS. Multivariate analysis showed that the best response to induction therapy did not achieve PR or better, EM-S were an independent adverses prognostic factor for PFS. The results of safety analysis showed that 16 cases had hematological adverse events, including 3 cases of grade 3/4 and 13 cases of grade 1/2. The most common non-hematological adverse events were nausea, vomiting, fatigue and abdominal distension, which were mild and tolerable.</p><p><strong>Conclusion: </strong>Pomalidomide-based chemotherapy is effective and well tolerated in MM patients with extramedullary disease.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 2","pages":"463-468"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144027425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Clinical Characteristics and Prognosis of Patients with IgD Multiple Myeloma].","authors":"Yong-Qian Zhang, Ji-Sheng Zhao, Xiao-Fang Wei, You-Fan Feng, Yuan Fu, Qiao-Lin Chen, Qi-Ke Zhang","doi":"10.19746/j.cnki.issn.1009-2137.2025.02.018","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.02.018","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the clinical characteristics and prognosis of patients with IgD multiple myeloma (MM).</p><p><strong>Methods: </strong>The clinical data of 8 patients with IgD MM admitted to Gansu Provincial Hospital from September 2013 to February 2023 were collected, and their clinical characteristics and prognosis were retrospectively analyzed and summarized.</p><p><strong>Results: </strong>Among the 8 enrolled patients, there were 4 males and 4 females, with a median age of 60 (44-74) years. All patients had symptoms of renal insufficiency and anemia. There were 3 cases of bone invasion, 3 cases of splenomegaly, 7 cases of IgD-λ type, and 1 case of IgD-κ type. FISH examination was performed in 7 cases, and 6 of them were positive for <i>1q21</i> . There were 6 cases in DS stage III and 2 cases in DS stage II; According to ISS staging, there were 6 cases in stage III, 1 case in stage II, and 1 case in stage I; According to R-ISS staging, there were 5 cases in stage III and 3 cases in stage II. All patients received bortezomib-based combination chemotherapy, with 1 case undergoing autologous stem cell transplantation (ASCT) and 2 cases receiving daratumumab in combination. The median treatment period was 6 (1-15) cycles. The short-term efficacy was evaluated after 4-6 courses of treatment. Among the 6 patients with assessable efficacy, 1 case experienced disease progression (PD), and 5 cases achieved complete remission (CR). The median follow-up time was 26 (11-33) months, and the median progression-free survival (PFS) and median overall survival (OS) of the patients were 11.25 (3-26) months and 18.5 (4-33) months, respectively. Among the 8 patients, 4 cases died. Among the deceased patients, 3 cases were in R-ISS stage III and 3 cases were <i>1q21</i> positive. 2 of the 5 patients with early CR died due to disease progression.</p><p><strong>Conclusion: </strong>The incidence of IgD MM is low, the symptoms of early renal damage, blood system damage and bone erosion in IgD MM patients are obvious, and the median survival time is short. ASCT and / or daratumumab may bring lasting relief for IgD MM patients, but large-scale clinical studies are still needed.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 2","pages":"437-441"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144039209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Sequence Analysis and Confirmation of an HLA Null Allele Generated by a Base Insertion].","authors":"Zhan-Rou Quan, Yan-Ping Zhong, Liu-Mei He, Bing-Na Yang, Hong-Yan Zou","doi":"10.19746/j.cnki.issn.1009-2137.2025.01.041","DOIUrl":"10.19746/j.cnki.issn.1009-2137.2025.01.041","url":null,"abstract":"<p><strong>Objective: </strong>To confirm the sequence of a null allele <i>HLA-C*08:127N</i> produced by a base insertion.</p><p><strong>Methods: </strong>PCR sequence-specific oligonucleotide probe (SSOP) and PCR sequence-based typing (SBT) were used for HLA routine detection, which discovered abnormal sequence maps of <i>HLA-C</i> in one acute myeloid leukemia patient. The sequence of the above loci was confirmed by next generation sequencing (NGS) technology.</p><p><strong>Results: </strong>The SSOP typing result showed that <i>HLA-C</i> locus was <i>C*03:04, C*08:01</i>, while the sequence was suspected to be inserted or deleted in exon 3 by SBT, and finally confirmed by NGS as <i>C*03:04, C*08:127N</i>.</p><p><strong>Conclusion: </strong>When base insertion produces HLA null alleles, SBT analysis software cannot provide correct results, but NGS technology can more intuitively obtain accurate HLA typing results.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 1","pages":"276-279"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143524828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[5-HT Promotes Proliferation and Inhibits Apoptosis of Megakarycytes through 5-HT2BR].","authors":"Hui-Min Kong, Yu-Rong Cen, Mo Yang, Qiang Peng, Jin-Qi Huang","doi":"10.19746/j.cnki.issn.1009-2137.2025.01.011","DOIUrl":"10.19746/j.cnki.issn.1009-2137.2025.01.011","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the effect of 5-hydroxytryptamine (5-HT) on the proliferation, apoptosis and colony-forming unit-megakaryocyte (CFU-MK) of Meg-01 cells and its possible mechanisms.</p><p><strong>Methods: </strong>The uptake and metabolism of 5-HT in Meg-01 cells were analysed by reverse-phase high-performance liquid chromatography (RP-HPLC) with electrochemical detection. The expression of 5-HT2B receptor (5-HT2BR) in megakaryocytes was detected by immunofluorescence staining. The cell proliferation and viability were measured by MTT and Trypan blue staining after Meg-01 cells were single-cultured or co-cultured with different concentrations of 5-HT/5-HT2BR inhibitor Ketanserin for 48 h. Meg-01 cells were incubated with 5-HT/ Ketanserin for 72 h, then the flow cytometry was used to detect early apoptosis of the cells and the activity of caspase-3. Using CFU-MK assay to investigate the effect of 5-HT on the differentiation of megakaryocytes.</p><p><strong>Results: </strong>5-HT could be uptaken by Meg-01 cells, and metabolized into 5-hydroxyindoleacetic acid (5-HIAA). The expression of 5-HT2BR on megakaryocytes could be detected after immunofluorescence staining. 5-HT could promote the proliferation of Meg-01 cells at a dose-dependent manner (<i>r</i> =0.82), with the most significant effect observed at a concentration of 200 nmol/L (<i>P</i> < 0.001). Trypan blue staining also indicated that 200 nmol/L 5-HT had the most significant effect on the viability of Meg-01 cells (<i>P</i> < 0.05). The proliferation of Meg-01 cells treated with 5-HT was increased compared with the untreated control (<i>P</i> < 0.001), while the combination of 5-HT with ketanserin downregulated this effect. 5-HT significantly reduced the early apoptosis rate (<i>P</i> < 0.001) and caspase-3 activity (<i>P</i> < 0.05) of Meg-01 cells, while addition of ketanserin significantly increased the early apoptosis rate of Meg-01 cells (<i>P</i> < 0.001) and caspase-3 activity also increased to some extent. 5-HT promoted the formation of CFU-MK in bone marrow cells in a dose-dependent manner (<i>r</i> =0.89). The addition of ketanserin reduced the promoting effect of 5-HT on CFU-MK formation (<i>P</i> < 0.01).</p><p><strong>Conclusion: </strong>There may be monoamine oxidase present in megakaryocytes, which can metabolize and decompose 5-HT into 5-HIAA. 5-HT may promote the proliferation and differentiation of megakaryocytes through 5-HT2BR. Besides, 5-HT can also reduce the apoptosis of megakaryocytes, and its anti-apoptotic effect may be mediated by 5-HT2BR and caspase-3 pathways.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 1","pages":"75-81"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143524816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[The Comparison of Efficacy and Safety between Venetoclax Combined with Demethylating Drugs and the \"3+7\" Drug Regimen for Acute Myeloid Leukemia].","authors":"Na Cui, Li-Jing Wang, Chang-Yong Yuan","doi":"10.19746/j.cnki.issn.1009-2137.2025.01.004","DOIUrl":"10.19746/j.cnki.issn.1009-2137.2025.01.004","url":null,"abstract":"<p><strong>Objective: </strong>To explore the efficacy and safety of venetoclax combined with demethylating drugs and intense chemotherapy in the treatment of acute myeloid leukemia (AML).</p><p><strong>Methods: </strong>The clinical data of 76 patients with AML treated in Qilu Hospital of Shandong University Dezhou Hospital from January 2019 to March 2024 were retrospectively analyzed. Patients were divided into observation group and control group. 38 patients in the observation group received venetoclax combined with demethylating drugs (decitabine or azacytidine) and 38 patients in the control group with the \"3+7\" intensive chemotherapy regimen. The primary endpoints of clinical observation were complete remission (CR), CR with incomplete hematologic recovery (CRi), partial remission (PR), non remission (NR), and overall response rate (ORR). Secondary endpoints were overall survival (OS) and drug safety.</p><p><strong>Results: </strong>After 2 courses of treatment, the CR+CRi rate in observation group and control group was 71.05% and 65.79%, respectively, and the ORR was 81.58% and 78.95%, respectively. After all courses of treatment, CR+CRi rate in the observation group and the control group was 73.68% and 78.95%, respectively, and the ORR was 81.58% and 84.21%, respectively, with no statistical significance between the two groups (<i>P</i> >0.05). After 1 course of treatment, there were statistically significant differences in the proportion and degree of myelosuppression, the duration of neutropenia and the duration of thrombocytopenia between the two groups (<i>P</i> < 0.05), while there were no statistically significant differences in the occurrence of neutropenia with fever between the two groups (<i>P</i> >0.05). The incidence of non-hematological adverse reactions was highest in infection (mainly pulmonary infection) and gastrointestinal reaction. Among the many adverse reactions, there were statistically significant differences in the infection and hypokalemia between the two groups (<i>P</i> < 0.05), the incidence of hypokalemia in observation group and control group was 42.11% and 15.79%, respectively, and the infection rate in observation group and control group was 73.68% and 94.74%, respectively. The median OS was 13.13(1.67-53.63) months in the observation group and 16.60(0.57-59.67) months in the control group.</p><p><strong>Conclusion: </strong>The combination of venetoclax and demethylating drugs has a low degree of myelosuppression, but a long recovery time, a response rate as good as that of intensive chemotherapy, and a lower infection rate. However, the incidence of hypokalemia is low in the intensive chemotherapy regimen, and the regimen significantly improves the long-term outcome of patients.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 1","pages":"25-31"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143523547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Expression and Biological Function of <i>SPOP</i> in Acute Myeloid Leukemia].","authors":"Xue-Ying Wan, Jing Xu, Xiao-Li Liu, Hong-Wei Wang","doi":"10.19746/j.cnki.issn.1009-2137.2025.01.005","DOIUrl":"10.19746/j.cnki.issn.1009-2137.2025.01.005","url":null,"abstract":"<p><strong>Objective: </strong>To study the expression of <i>SPOP</i> in patients with acute myeloid leukemia (AML) and its effect on proliferation, apoptosis and cycle of AML cells.</p><p><strong>Methods: </strong>RT-qPCR was used to detect the expression of <i>SPOP</i> mRNA in bone marrow samples of patients with newly diagnosed AML and normal controls. The stable overexpression of <i>SPOP</i> in AML cell lines THP-1 and U937 were constructed by liposome transfection. The effect of <i>SPOP</i> on cell proliferation was detected by CCK-8, and the effect of <i>SPOP</i> on apoptosis and cell cycle was detected by flow cytometry. The expressions of anti-apoptotic protein Bcl-2 and apoptotic protein Bax, Caspase3 were detected by Western blot.</p><p><strong>Results: </strong>The median expression level of <i>SPOP</i> mRNA in normal control group was 0.993 1(0.6303, 1.433), while that in AML group was 0.522 1(0.242 2, 0.723 7). The expression level of <i>SPOP</i> in AML group was significantly lower than that in normal control group ( <i>P</i> < 0.001). After the overexpression of <i>SPOP</i>, the proportion of apoptotic cells in the U937 overexpression group and THP-1 overexpression group was 10.9%±0.3% and 4.6%±015%, which were higher than 8.9%±0.3% and 3.0%±0.30% in the Empty Vector group, respectively (both <i>P</i> < 0.05). The expression of Caspase3 in U937 overexpression group and THP-1 overexpression group was 1.154±0.086 and 1.2±0.077, which were higher than 1 in Empty Vector group, respectively (both <i>P</i> < 0.05). The ratio of Bax/Bcl-2 in U937 overexpression group and THP-1 overexpression group was 1.328±0.057 and 1.669±0.15, which were higher than 1 in Empty Vector group, respectively (both <i>P</i> < 0.05). In the cell proliferation experiment, the number of cells in the U937 overexpression group and THP-1 overexpression group were both slightly lower than those in the Empty Vector group, but the differences were not statistically significant (<i>P</i> >0.05). In the cell cycle experiment, the proportion of G₁ cells in the U937 overexpression group and THP-1 overexpression group were both slightly higher than those in the Empty Vector group, but the differences were not statistically significant (<i>P</i> >0.05).</p><p><strong>Conclusion: </strong><i>SPOP</i> can promote the apoptosis of leukemic cells, and its mechanism may be related to down-regulation of Bcl-2 expression and up-regulation of Bax and Caspase3 expression.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 1","pages":"32-38"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143524745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Advances in Study of Erythroblastic Island Macrophages--Review].","authors":"Zhao-Hui Wang, Shuang Ding","doi":"10.19746/j.cnki.issn.1009-2137.2025.01.044","DOIUrl":"10.19746/j.cnki.issn.1009-2137.2025.01.044","url":null,"abstract":"<p><p>Bone marrow microenvironment is the environment in which hematopoietic stem cells live, mainly composed of bone marrow stromal cells, microvessels, nerves, and cytokines secreted by stromal cells. The bone marrow microenvironment plays a crucial role in the self-renewal, directed differentiation and proliferation of hematopoietic stem cells and the regulation of proliferation, differentiation and maturation of hematopoietic cells. A class of macrophages exists in the bone marrow microenvironment, the bone marrow-resident tissue macrophages, which plays a crucial role in maintaining homeostasis <i>in vivo</i>, and three subpopulations of bone marrow-resident tissue macrophages have been characterized: erythroblastic island macrophages (EIMs), hematopoietic stem cell niche macrophages, and bone macrophages. This review focuses on the functions, surface markers and modeling of EIMs.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 1","pages":"292-295"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143524841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Clinical and Laboratory Characteristics of Streptococcus mitis Causing Bloodstream Infection in Children with Hematological Disease].","authors":"Yu-Long Fan, Guo-Qing Zhu, Zhi-Ying Tian, Yan-Xia Lyu, Zhao Wang, Ye Guo, Wen-Yu Yang, Qing-Song Lin, Xiao-Juan Chen","doi":"10.19746/j.cnki.issn.1009-2137.2025.01.043","DOIUrl":"10.19746/j.cnki.issn.1009-2137.2025.01.043","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the risk factors, clinical characteristics, and bacterial resistance of bloodstream infections caused by <i>Streptococcus mitis</i> in children with hematological disease, so as to provide a reference for infection control.</p><p><strong>Methods: </strong>The clinical information and laboratory findings of pediatric patients complicated with blood cultures positive for <i>Streptococcus mitis</i> from January 2018 to December 2020 in the Institute of Hematology & Blood Diseases Hospital were searched and collected. The clinical characteristics, susceptibility factors, and antibiotic resistance of the children were retrospectively analyzed.</p><p><strong>Results: </strong>Data analysis from 2018 to 2020 showed that the proportion of <i>Streptococcus mitis</i> isolated from bloodstream infections in children (≤14 years old) with hematological diseases was the highest (19.91%) and significantly higher than other bacteria, accounting for 38.64% of Gram-positive cocci, and presented as an increasing trend year by year. A total of 427 children tested positive blood cultures, including 85 children with bloodstream infections caused by <i>Streptococcus mitis</i> who tested after fever. Most children experienced a recurrent high fever in the early and middle stages (≤6 d) of neutropenia and persistent fever for more than 3 days. After adjusting the antibiotics according to the preliminary drug susceptibility results, the body temperature of most children (63.5%) returned to normal within 4 days. The 85 children were mainly diagnosed with acute myeloid leukemia (AML), accounting for 84.7%. The proportion of children in the neutropenia stage was 97.7%. The incidence of oral mucosal damage, lung infection, and gastrointestinal injury symptoms was 40%, 31.8%, and 27.1%, respectively. The ratio of elevated C-reactive protein (CRP) and procalcitonin was 65.9% and 9.4%, respectively. All isolated strains of <i>Streptococcus mitis</i> were not resistant to vancomycin and linezolid, and the resistance rate to penicillin, cefotaxime, levofloxacin, and quinupristin-dalfopristin was 10.6%, 8.2%, 9.4%, and 14.1%, respectively. None of children died due to bloodstream infection caused by <i>Streptococcus mitis</i>.</p><p><strong>Conclusion: </strong>The infection rate of <i>Streptococcus mitis</i> is increasing year by year in children with hematological diseases, especially in children with AML. Among them, neutropenia and oral mucosal damage after chemotherapy are high-risk infection factors. The common clinical symptoms include persistent high fever, oral mucosal damage, and elevated CRP. Penicillin and cephalosporins have good sensitivity. Linezolid, as a highly sensitive antibiotic, can effectively control infection and shorten the course of disease.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 1","pages":"286-291"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143524898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}